On August 9, 2007, Rising filed an Abbreviated New Drug Application titled ANDA078306, a filing that signals the company's entry into the generic pharmaceutical sector. While the specific substance remains undisclosed, such regulatory progress typically signals Rising's expansion into the market and could set the stage for future revenue growth through patent expirations.